• Explore /
  • Poster
  • / A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).

A randomized, double-blind, placebo-controlled, phase 3 study of rituximab with or without ibrutinib for Waldenstrom’s macroglobulinemia (PCYC-1127-CA).

Abstract Poster

Authors

Meletios Dimopoulos

Meletios A. Dimopoulos

Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece

Meletios A. Dimopoulos , Xavier Leleu , Jeffrey Matous , David MacDonald , Judith Trotman , Albert Oriol , Chaim Shustik , Alessandra Tedeschi , Ramon Garcia-Sanz , Leonard T. Heffner , Shuo Ma , Beatrice Mahe , Constantine Tam , Olivier Tournilhac , Jianling Li , Priyanka Singh , Elizabeth Bilotti , Thorsten Graef , Steven P. Treon , Christian Buske

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lymphoma and Plasma Cell Disorders

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Lymphoma

Clinical Trial Registration Number

NCT02165397

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS8599)

DOI

10.1200/jco.2015.33.15_suppl.tps8599

Abstract #

TPS8599

Poster Bd #

418a

Abstract Disclosures

Similar Posters

First Author: Ariela Noy

First Author: Laurie Helen Sehn

First Author: Jeff P. Sharman

First Author: Michael Wang